Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行業原文收錄 · 來源發佈：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertak
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。